Regulatory momentum Liberate Medical holds FDA Breakthrough Device Designation, FDA EUA, and CE marking for VentFree, signaling strong regulatory alignment and potential faster access paths in key markets. Leverage this to engage hospitals and procurement teams seeking innovative devices with accelerated clearance timelines.

Clinical impact VentFree aims to reduce time on mechanical ventilation by strengthening expiratory muscles, which can lower morbidity, mortality risk, and ICU costs. Position offerings to respiratory care directors and intensivists as a cost-saving, patient-outcome improving technology with potential payer appeal.

Strategic partnerships Recent Series B funding and board additions from Scientific Health Development and strategic investors suggest favorable investor sentiment and access to broader distribution networks. Explore co-sell/ OEM opportunities with larger medtech players and contract manufacturers to scale adoption.

Production acceleration Existing manufacturing collaboration with Valtronic and plans for rapid scale point to capability to meet growing demand. Target hospitals and group purchasing organizations with assurances of supply continuity, scalable manufacturing, and rapid deployment cycles.

Market fit emphasis VentFree occupies a niche at the intersection of non-invasive neuromuscular stimulation and critical care. Prioritize outreach to hospitals facing high ventilator-associated complications, and to competitors’ customers seeking non-invasive alternatives with potential cost savings and shortened ventilation durations.